The European Commission has approved olezarsen for adults with severe hypertriglyceridaemia, following Phase 3 results showing reduced triglyceride levels and fewer acute pancreatitis events.

Sobi has announced that the European Commission (EC) has approved Tryngolza™ (olezarsen) for adults with severe hypertriglyceridaemia (sHTG), making it the first and only RNA-targeted therapy authorised in the EU for patients with fasting triglyceride levels ≥880 mg/dL (≥10 mmol/L).
sHTG is defined as fasting triglyceride levels ≥500 mg/dL (≥5.65 mmol/L). However, levels ≥880 mg/dL (≥10 mmol/L) are associated with a high risk of acute pancreatitis and other comorbidities. Approximately 2 million people are estimated to be living with sHTG across the EU5, including around 700,000 with triglyceride levels ≥880 mg/dL (≥10 mmol/L).
The medicine is indicated as an adjunct to diet, in combination with other lipid-lowering therapies. The approval expands Tryngolza’s existing EU marketing authorisation for familial chylomicronaemia syndrome (FCS) to a broader patient population, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2026.
The decision is based on the Phase 3 CORE and CORE2 trials, sponsored by Ionis Pharmaceuticals in collaboration with the TIMI Study Group. A pre-specified analysis demonstrated a statistically significant reduction of up to 73 percent in triglyceride levels at six months compared with placebo (p<0.001), with reductions sustained through 12 months.
In a pooled analysis of the CORE and CORE2 studies, Tryngolza demonstrated a significant 83 percent reduction in adjudicated acute pancreatitis events over 12 months compared with placebo (p<0.001).
Talking on the approval, Lydia Abad-Franch MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi, said, “The European Commission’s approval of Tryngolza for the treatment of sHTG is an important step forward for patients in Europe who remain at increased risk of acute pancreatitis despite diet and existing lipid-lowering therapies”.
Tryngolza is an RNA-targeted medicine designed to reduce the production of apolipoprotein C-III, a liver-produced protein involved in triglyceride metabolism. It is administered once monthly via subcutaneous injection.



No comments yet